Hercules Capital Reports Fourth Quarter and Full-Year 2024 Financial Results

$HCXY
$HTGC
Investment Managers
Finance
Get the next $HCXY alert in real time by email

Record Full-Year 2024 Total Investment Income of $493.6 Million, an Increase of 7.1% Year-over-Year

Record Full-Year 2024 Net Investment Income "NII" of $325.8 Million, an Increase of 7.2% Year-over-Year

Record Full-Year 2024 Gross Fundings of $1.81 Billion, an Increase of 13.0% Year-over-Year

Q4 2024 NII of $81.1 Million, or $0.49 per Share, provides 123% Coverage of the Base Cash Distribution

Q4 2024 Total Gross Debt and Equity Commitments of $619.5 Million

Q4 2024 Total Gross Fundings of $468.5 Million

Conservative Balance Sheet Management with Net GAAP Leverage of 83.9% and Net Regulatory Leverage of 69.9%

Inclusive of the Adviser Funds Managed by Hercules Adviser LLC, its Wholly-Owned Subsidiary, Hercules had over $1.1 Billion of Available Liquidity as of Year End

Announced a New Supplemental Cash Distribution for 2025 of $0.28 per Share, Payable over Four Quarters

Undistributed Earnings Spillover of $163.6 Million, or $0.96(1) per Ending Shares Outstanding

Approximately $4.8 Billion of Assets Under Management, an Increase of 14.2% Year-over-Year(2)

Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2024. The earnings release can be accessed at Hercules' Investor Relations website at https://investor.htgc.com/financial-information/financial-results.

Footnotes:

(1) $0.99 per Weighted Average Shares Outstanding

(2) Assets under management includes assets managed by Hercules and the Adviser Subsidiary

Conference Call

Hercules has scheduled its fourth quarter and full-year 2024 financial results conference call for February 13, 2025 at 2:00 p.m. PT (5:00 p.m. ET). To participate via telephone, please register here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. While not required, it is recommended you join 10 minutes prior to the event start. A live webcast of the fourth quarter and full-year 2024 financial results conference call will also be available on the investor relations section of the Company's website at investor.htgc.com. An archived webcast replay will be available on the Company's website for at least 30 days following the conference call.

About Hercules Capital, Inc.

Hercules Capital, Inc. (NYSE:HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology and life sciences industries. Since inception (December 2003), Hercules has committed more than $21 billion to over 670 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact info@htgc.com, or call 650.289.3060.

Hercules, through its wholly owned subsidiary business, Hercules Adviser LLC (the "Adviser Subsidiary"), also maintains an asset management business through which it manages investments for external parties ("Adviser Funds"). The Adviser Subsidiary is registered as an investment adviser under the Investment Advisers Act of 1940.

Hercules' common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol "HTGC." In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE:HCXY).

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We may use words such as "anticipates," "believes," "expects," "intends," "will," "should," "may" and similar expressions to identify forward-looking statements. Forward-looking statements are not guarantees of future performance and should not be relied upon in making any investment decision. Such statements are based on currently available operating, financial and competitive information and are subject to various risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations. While we cannot identify all such risks and uncertainties, we urge you to read the risks discussed in our Annual Report on Form 10-K and other materials that we publicly file with the Securities and Exchange Commission. Any forward-looking statements made in this press release are made only as of the date hereof. Hercules assumes no obligation to update any such statements in the future.

Michael Hara

Investor Relations and Corporate Communications

Hercules Capital, Inc.

650-433-5578

mhara@htgc.com

Get the next $HCXY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HCXY
$HTGC

CompanyDatePrice TargetRatingAnalyst
12/12/2024$19.50 → $21.50Mkt Perform → Outperform
Keefe Bruyette
1/16/2024$17.00 → $17.50Buy → Neutral
Compass Point
11/21/2023$17.00Neutral
UBS
8/30/2023$17.50Neutral → Buy
Compass Point
8/4/2023$13.50 → $17.00Underperform → Mkt Perform
Keefe Bruyette
4/6/2023$16.00Neutral → Overweight
Piper Sandler
3/13/2023$14.50 → $10.50Mkt Perform → Underperform
Keefe Bruyette
7/29/2022Outperform → Perform
Oppenheimer
More analyst ratings

$HCXY
$HTGC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

    Includes $30M at Close to Refinance Existing Debt Facility Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), for up to $200 million. Access to the additional capital strengthens Savara's balance sheet following the submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP). If Priority Review is granted by the FDA, MOLBREEVI could potentially be approved by the end of the year. The Comp

    $HTGC
    $SVRA
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Hercules Capital Closes Offering of $287.5 Million of Convertible Unsecured Notes

    Convertible Unsecured Notes due 2028 Initially Assigned a BBB+ by Kroll Bond Rating Agency Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has closed a private offering of $287.5 million aggregate principal amount of its 4.750% Convertible Unsecured Notes due 2028 (the "Convertible Notes"), which amount includes the additional $37.5 million aggregate principal amount of Convertible Notes issued pursuant to the initial purchasers' exercise in full of its overallotment option. The Convertible Notes were sold only to qualified institutional buyers (as defined in the Securities Act of 1933, as amended (the "Securities Act")) pursuant to Rule 144A under

    $HCXY
    $HTGC
    Investment Managers
    Finance
  • Hercules Capital Receives Investment Grade Rating Upgrade to BBB (high) with Revised Outlook to Stable from Morningstar DBRS

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Morningstar DBRS ("DBRS") has upgraded Hercules' investment grade credit and corporate rating to BBB (high) from BBB with a trend revision from Positive to Stable, as well as its underlying analysis. "We are very pleased that DBRS has upgraded our investment grade credit and corporate rating to BBB (high) with a revised outlook to stable," stated Seth Meyer, chief financial officer of Hercules. "This

    $HCXY
    $HTGC
    Investment Managers
    Finance

$HCXY
$HTGC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HCXY
$HTGC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$HCXY
$HTGC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HCXY
$HTGC
SEC Filings

See more

$HCXY
$HTGC
Leadership Updates

Live Leadership Updates

See more
  • Revelation Partners Expands Team with Hire of Andrew Olson, Partner, Chief Financial Officer & Chief Operating Officer

    SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer

    $HTGC
    $TPVG
    Investment Managers
    Finance
    Other Consumer Services
    Consumer Discretionary
  • Hercules Capital Announces the Appointment of Mr. Nikos Theodosopoulos to Its Board of Directors

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc

    $HCXY
    $HTGC
    Investment Managers
    Finance
  • Hercules Capital Announces the Appointment of Ms. DeAnne Aguirre to Its Board of Directors

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o

    $HCXY
    $HTGC
    Investment Managers
    Finance

$HCXY
$HTGC
Financials

Live finance-specific insights

See more
  • Hercules Capital Reports Fourth Quarter and Full-Year 2024 Financial Results

    Record Full-Year 2024 Total Investment Income of $493.6 Million, an Increase of 7.1% Year-over-Year Record Full-Year 2024 Net Investment Income "NII" of $325.8 Million, an Increase of 7.2% Year-over-Year Record Full-Year 2024 Gross Fundings of $1.81 Billion, an Increase of 13.0% Year-over-Year Q4 2024 NII of $81.1 Million, or $0.49 per Share, provides 123% Coverage of the Base Cash Distribution Q4 2024 Total Gross Debt and Equity Commitments of $619.5 Million Q4 2024 Total Gross Fundings of $468.5 Million Conservative Balance Sheet Management with Net GAAP Leverage of 83.9% and Net Regulatory Leverage of 69.9% Inclusive of the Adviser Funds Managed by Hercules Adviser LLC, its

    $HCXY
    $HTGC
    Investment Managers
    Finance
  • Hercules Capital Announces Date for Release of Fourth Quarter and Full-Year 2024 Financial Results and Conference Call

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its fourth quarter and full-year 2024 financial results conference call for Thursday, February 13, 2025, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. To participate via telephone, please register here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can b

    $HCXY
    $HTGC
    Investment Managers
    Finance
  • Hercules Capital Reports Third Quarter 2024 Financial Results

    Record Q3 2024 Total Investment Income of $125.2 Million, an Increase of 7.3% Year-over-Year Q3 2024 Net Investment Income "NII" of $83.2 Million, or $0.51 per Share, an Increase of 8.3% Year-over-Year Q3 2024 NII Provides 128% Coverage of the Base Cash Distribution Q3 2024 Total Gross Debt and Equity Commitments of $430.7 Million Q3 2024 Total Gross Fundings of $272.0 Million Conservative Balance Sheet Management with Net GAAP Leverage of 92.5% and Net Regulatory Leverage of 83.0% Undistributed Earnings Spillover of $152.1 Million, or $0.94(1) per Ending Shares Outstanding Approximately $4.6 Billion of Assets Under Management, an Increase of 10.9% Year-over-Year(2) Hercules Capital

    $HCXY
    $HTGC
    Investment Managers
    Finance

$HCXY
$HTGC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more